StockVS

Wellgistics Health, Inc. (WGRX) 주식 분석

의료

Wellgistics Health, Inc.

$3.82

+$3.74 (+4519.11%)

최종 업데이트: 2026년 5월 26일

가격 추이

분석

회사 개요

Wellgistics Health, Inc. is a specialized entity operating within the United States pharmaceutical distribution landscape, focusing on the wholesale and distribution of pharmaceutical products to both pharmaceutical manufacturers and independent retail pharmacies. The company's portfolio encompasses the supply of branded and generic pharmaceuticals, alongside over-the-counter healthcare and consumer products, positioning it firmly within the Healthcare sector as a Pharmaceutical Retailer. As of the latest available data, the company holds a market capitalization of $15.17M, supported by an annual revenue of $23.34M, while specific employee count details are not disclosed in the provided records. The valuation metrics indicate that Wellgistics Health operates as a micro-cap entity, suggesting a limited scale in the broader healthcare distribution market compared to major industry peers.

재무 건전성

The company reported a total revenue of $23.34M for the trailing twelve months, yet this revenue generation was accompanied by a net income loss of $-101,274,528 and an EBITDA of $-77,983,768, revealing a significant structural gap where operating expenses far exceed gross revenue. Despite the substantial net loss, the company generated positive free cash flow of $7.64M, which provides a degree of financial flexibility for operational continuity despite accounting losses. The gross margin stands at -27.5%, indicating that the cost of goods sold exceeds total revenue, a critical indicator of severe cost inefficiency or inventory valuation issues inherent to the business model. Furthermore, the operating margin is recorded at -766.0% and the profit margin at 0.0%, figures that collectively demonstrate a complete inability to cover operating expenses or generate profit from sales. On the liquidity front, the company holds only $42,571 in cash against a total debt obligation of $24.58M, resulting in a debt-to-equity ratio that is not calculable due to the negative equity position. This imbalance is further highlighted by a current ratio of 0.10, which signals a precarious short-term liquidity situation where current assets are insufficient to cover current liabilities. Additionally, the return on assets is -115.6% and the return on equity is not available, metrics that underscore the ineffective deployment of capital and the substantial erosion of shareholder value.

밸류에이션 평가

The trailing P/E ratio and forward P/E ratio are both listed as N/A, reflecting the company's status as a non-profitable entity where traditional earnings-based valuation multiples are inapplicable. The price-to-book ratio is -1.02, a negative figure that indicates the company's market value is below its book value and suggests the market does not assign a premium to its assets. Alternative valuation metrics such as the price-to-sales ratio of 0.65 and an EV/EBITDA of -0.48 provide insight into the company's pricing relative to sales volume, though the negative EV/EBITDA reinforces the fundamental challenges in generating economic profit. Regarding price volatility, the stock has traded between a 52-week high of $7.04 and a 52-week low of $0.10, illustrating an extreme range of movement typical of small-cap stocks with limited market capitalization. Without a specific beta value provided, the historical price action between these two extremes suggests high sensitivity to market sentiment and liquidity constraints rather than systematic market movements.

Growth & Income

The revenue growth year-over-year is -86.5%, while the earnings growth year-over-year is N/A, indicating a contraction in the core business operations without a clear trajectory toward profitability. Because the company reports a net loss, the concept of a dividend yield and payout ratio is N/A, meaning the company is not distributing cash to shareholders. Instead of paying dividends, the company is in a position where any generated free cash flow is necessary to cover operational deficits and debt obligations rather than being available for distribution to investors. The overall growth and income profile for Wellgistics Health, Inc. is characterized by significant revenue contraction and an absence of earnings or dividend income, presenting a challenging landscape for income-focused investors.

동종업체 비교

Wellgistics Health, Inc. (WGRX) 은(는) 약국 산업에서 운영됩니다. 시가총액 기준으로 가장 가까운 동종업체와의 비교는 다음과 같습니다:

기업명 티커 시가총액 PER
Wellgistics Health, Inc. WGRX $9.60M N/A
High Tide Inc. HITI $207.44M N/A
TelyRx Holdings Inc. TELY.TO $136.78M N/A
PetMed Express, Inc. PETS $45.37M N/A

이 분석은 AI가 생성한 것으로 정보 제공 목적으로만 사용되며 투자 조언이 아닙니다. 데이터가 지연되거나 부정확할 수 있습니다. 투자 결정을 내리기 전에 항상 직접 조사하고 자격을 갖춘 재무 상담사와 상담하세요.

Wellgistics Health, Inc. 소개

Wellgistics Health, Inc. engages in the wholesale and distribution of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company distributes branded and generic pharmaceuticals, as well as over-the-counter healthcare and consumer products. It also offers third-party logistics services that include warehousing, inventory management, pick and pack, and shipping to small and mid-size pharmaceutical manufacturers. It also operates DelivMeds platform that serves as a pharmaceutical hub to facilitate the transfer of prescriptions and provide backend clinical concierge services to a network of independent pharmacies; and operates a retail community specialty. The company was formerly known as Danam Health, Inc. and changed its name to Wellgistics Health, Inc. in October 2024. Wellgistics Health, Inc. was incorporated in 2022 and is based in Tampa, Florida.

회사 설명은 영어로 표시됩니다.

웹사이트 방문 →

주요 지표

시가총액
$9.60M
PER
N/A
52주 최고가
$4.25
52주 최저가
$0.07
평균 거래량
31.33M

데이터는 yfinance를 통해 Yahoo Finance에서 제공됩니다. 매일 업데이트.

기업 정보

산업
약국
거래소
NASDAQ
국가
United States